Volume : 09, Issue : 01, January – 2022
Title:
14.OUTCOME OF PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION DISCHARGE ON NEUROHORMONAL ANTAGONIST
Authors :
Dr Ahmad Aneeq, Dr Maryam Saghir, Dr Hassam Ahmed, Dr Numair Mahmood,Dr Haleema Saadia
Abstract :
Introduction: Heart failure (HF) is an important health problem with elevated socio-health care costs. This disease is highly prevalent in the people over the age of 65 years and constitutes the first cause of hospitalization in this population. Objectives: The main objective of the study is to find the outcome of patients with heart failure with preserved ejection fraction discharge on neurohormonal antagonist. Material and methods: This randomized control trial was conducted in QAMC Bahawalpur during June 2021 to November 2021. The data was collected with the permission of ethical committee of hospital. The present analysis included all patients discharged alive after an episode of AHF with a LVEF of 50% or more recorded in an echocardiography performed during the 6 months prior to decompensation or that had been recorded during the current admission. Results: The data was collected from 100 patients of both genders. The mean age was 82.45 ± 4.56 years. The group receiving ANHD was younger, had a higher presence of hypertension, diabetes mellitus and ischemic cardiomyopathy, less functional capacity, and decompensation was more frequent due to tachyarrhythmia, hypertensive crisis or incompliance with pharmacological or dietetic treatments. Conclusion: It is concluded that anti-neuro hormonal drugs do not seem to reduce mortality or adverse events preserved ejection fraction patients, only renin-angiotensin-aldosterone-system inhibitors could provide some benefits, reducing the risk of hospitalization for AHF
Cite This Article:
Please cite this article in press Ahmad Aneeq et al, Outcome Of Patients With Heart Failure With Preserved Ejection Fraction Discharge On Neurohormonal Antagonist., Indo Am. J. P. Sci, 2022; 09(01).
Number of Downloads : 10
References:
1. Arrigo, M., Jessup, M., Mullens, W. et al. Acute heart failure. Nat Rev Dis Primers 6, 16 (2020). https://doi.org/10.1038/s41572-020-0151-7
2. Josep Tost, Pere Llorens, Gad Cotter, Beth Davison, Javier Jacob, Víctor Gil, Pablo Herrero, Francisco Javier Martín-Sánchez, Ruxandra Donea, Beatriz Rodríguez, Francisco Javier Lucas-Imbernon, Juan Antonio Andueza, Ana Belén Mecina, Raquel Torres-Gárate, Pascual Piñera, Aitor Alquézar-Arbé, Begoña Espinosa, Alexandre Mebazaa, Ovidiu Chioncel, Òscar Miró, Outcomes of patients with heart failure with preserved ejection fraction discharged on treatment with neurohormonal antagonists after an episode of decompensation, European Journal of Internal Medicine,Volume 94,2021,Pages 73-84,ISSN 0953-6205,https://doi.org/10.1016/j.ejim.2021.07.013.
3. Borlaug BA, Melenovsky V, Koepp KE. Inhaled Sodium Nitrite Improves Rest and Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction. Circ Res 2016; 119:880.
4. Hoendermis ES, Liu LC, Hummel YM, et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J 2015; 36:2565.
5. Ò Miró, X Rossello, V Gil, FJ Martín-Sánchez, P Llorens, P Herrero-Puente, et al. Predicting 30-day mortality for patients with acute heart failure in the emergency department: a cohort study. Ann Inter Med, 167 (2017), pp. 698-705
6. Takagi, K. et al. Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: results from the OptimaCC trial. Eur. J. Heart Fail. https://doi.org/10.1002/ejhf.1600 (2019).
7. Deniau, B. et al. Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamics. Eur. J. Heart Fail. 14, e0220866 (2019).
8. Konstam, M. A. et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 297, 1319–1331 (2007).
9. Teerlink, J. R. et al. Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure. J. Am. Coll. Cardiol. 67, 1444–1455 (2016).
10. Allen, L. A. et al. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circ. Cardiovasc. Qual. Outcomes 4, 389–398 (2011).